Repligen (NASDAQ:RGEN) Issues FY 2024 Earnings Guidance

Repligen (NASDAQ:RGEN) updated its FY 2024 earnings guidance on Tuesday. The company provided EPS guidance of 1.500-1.580 for the period, compared to the consensus EPS estimate of 1.430. The company issued revenue guidance of $630.0 million-$639.0 million. Repligen also updated its FY24 guidance to $1.50-1.58 EPS.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a research note on Thursday, September 26th. Wells Fargo & Company initiated coverage on Repligen in a research report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 target price on the stock. Wolfe Research initiated coverage on Repligen in a research report on Thursday. They issued a “peer perform” rating on the stock. JPMorgan Chase & Co. upped their price objective on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Wednesday, July 31st. Finally, StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a research report on Wednesday. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Repligen currently has a consensus rating of “Moderate Buy” and a consensus price target of $190.25.

Repligen Stock Down 6.2 %

Shares of RGEN stock traded down $8.88 during mid-day trading on Friday, hitting $133.55. The stock had a trading volume of 136,573 shares, compared to its average volume of 657,876. Repligen has a 12-month low of $113.50 and a 12-month high of $211.13. The firm has a market capitalization of $7.48 billion, a P/E ratio of -361.50, a price-to-earnings-growth ratio of 4.36 and a beta of 0.96. The firm’s 50-day moving average is $141.59 and its two-hundred day moving average is $144.78. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. The firm had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. Repligen had a positive return on equity of 3.92% and a negative net margin of 3.36%. The firm’s quarterly revenue was up 9.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.23 EPS. On average, analysts predict that Repligen will post 1.44 earnings per share for the current fiscal year.

Insider Activity at Repligen

In other news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the transaction, the director now directly owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. This represents a 13.70 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.20% of the stock is currently owned by corporate insiders.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.